STOML2

Across TCGA pan-cancer cohorts, STOML2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated STOML2 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher STOML2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STOML2 expression acts as an unfavorable survival marker.

THCA, STAD, and LUAD are the cancer types where STOML2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.032	0.950	<.001	48	view →
STAD	OS	Median	All	0.001	0.667	<.001	36	view →
LUAD	DFS	Median	II,III,IV	0.112	0.685	<.001	33	view →
COAD	OS	Median	All	0.111	0.871	<.001	24	view →
LUSC	OS	Median	All	0.173	0.724	.012	15	view →
HNSC	OS	Median	IV	0.013	0.733	<.001	12	view →
SKCM	DFS	Median	II,III,IV	0.192	0.685	.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

STOML2–THCA (OS)

Open the THCA breakdown →